Quick Take
Beam Therapeutics (BEAM) intends to raise $100 million from the sale of its common stock, per an amended registration statement.
The company is advancing a pre-clinical set of programs for the treatment of various diseases that may possibly be treated via gene editing of a single base pair of genes.
BEAM has promise, but the IPO is extremely early stage, genetic treatments are proceeding very slowly through the US FDA and the IPO may be more suited to institutional, long-term hold investors.
Company & Technology
Cambridge, Massachusetts-based Beam was founded